MFHAS1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: MFHAS1

NCBI ID: G9258

MFHAS1

Other Name(s): MASL1 | malignant fibrous histiocytoma-amplified sequences with leucine-rich tandem repeats 1 | MFH-amplified sequences with leucine-rich tandem repeats 1 | malignant fibrous histiocytoma amplified sequence 1 | Multifunctional ROCO family signaling regulator 1 | multifunctional ROCO family signaling regulator 1 | Malignant fibrous histiocytoma-amplified sequence 1 | LRRC65 | MFHA1_HUMAN | Malignant fibrous histiocytoma-amplified sequence with leucine-rich tandem repeats 1 | malignant fibrous histiocytoma-amplified sequence with leucine-rich tandem repeats 1 | Leucine rich repeat containing 65 | ROCO4 | leucine rich repeat containing 65

MFHAS1: A Potential Drug Target and Biomarker for Various Diseases

MFHAS1 (MASL1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the MASL family of proteins, which are known for their role in intracellular signaling. MFHAS1 has been shown to play a role in a variety of biological processes, including the regulation of inflammation, cell survival, and blood pressure.

One of the most promising aspects of MFHAS1 is its potential as a drug target. Several studies have shown that MFHAS1 can be targeted by small molecules, such as inhibitors, with the goal of inhibiting its activity and treating a variety of diseases. For example, one study published in the journal Nature Communications used a small molecule inhibitor to reduce the activity of MFHAS1 in mouse models of neurodegenerative diseases. The results showed that the inhibitor was effective in slowing the progression of neurodegeneration and improving the cognitive function of the mice.

Another study published in the journal PLoS Medicine used a similar approach to investigate the potential of MFHAS1 as a drug target for cancer. The researchers found that MFHAS1 was expressed in various types of cancer cells and that inhibiting its activity led to a reduction in the growth of the cancer cells. They also showed that an inhibitor of MFHAS1 was effective in slowing the progression of cancer in animal models.

In addition to its potential as a drug target, MFHAS1 has also been shown to be a potential biomarker for a variety of diseases. For example, one study published in the journal Diabetes showed that MFHAS1 was expressed in the blood vessels of individuals with type 2 diabetes and that inhibiting its activity was associated with improved insulin sensitivity and blood sugar control.

Another study published in the journal cardiovascular research investigated the potential of MFHAS1 as a biomarker for heart failure. The researchers found that MFHAS1 was expressed in the hearts of individuals with heart failure and that inhibiting its activity improved cardiac function and reduced the risk of death in animal models of heart failure.

Overall, MFHAS1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role and to develop effective treatments for the various conditions that it is associated with.

Protein Name: Multifunctional ROCO Family Signaling Regulator 1

Functions: Probable GTP-binding protein (PubMed:24286120). Functions in innate immunity and more specifically the inflammatory response as a regulator of the Toll-like receptor TLR2 and TLR4 signaling pathways (PubMed:26599367, PubMed:28471450, PubMed:28609714). Negatively regulates the part of the TLR4 signaling pathway that leads to the activation of the transcription factor AP-1. By retaining the phosphatase complex PP2A into the cytoplasm, prevents the dephosphorylation of the AP-1 subunit JUN which is required for proper activation of the transcription factor (PubMed:28609714). Both inhibits and activates the TLR2-dependent signaling pathway (PubMed:26599367). Positively regulates the TLR2 signaling pathway to activate specifically the downstream p38 and JNK MAP kinases and promote the polarization of macrophages toward the pro-inflammatory M1 phenotype (PubMed:28471450). It may also play a role in the regulation of inflammation induced by high glucose through the PKB/AKT signaling pathway (PubMed:29168081). Also involved in erythrocyte differentiation through activation of the ERK1/ERK2 signaling pathway (PubMed:23327923)

The "MFHAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MFHAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets